Anti-CTLA-4 blockade enhances the anti-tumour efficacy of E6-RHDV-VLP-PADRE immunisation.

PD-1/CTLA-4 blockade increases the number of intra-tumor high endothelial venules, and enhances RANTES production in tumors.

Shi-Dong Ma (2746609)
Xuequn Xu (2746615)
Richard Jones (774144)
Henri-Jacques Delecluse (166065)
Nicholas A. Zumwalde (2746606)
Akshat Sharma (2746612)
Jenny E. Gumperz (215318)
Shannon C. Kenney (184312)

May 2016

A). Lymphomas from EBV-infected cord blood-humanized NSG mice treated with or without PD-1...

Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model

Field, Cameron S.
Hunn, Martin K.
Ferguson, Peter M.
Ruedl, Christiane
Ancelet, Lindsay R.
Hermans, Ian F.

January 2017

Vaccine-mediated cancer treatment is unlikely to induce long-term survival unless suppressive mechan...

Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer

van Hooren, Luuk
Sandin, Linda C
Moskalev, Igor
Ellmark, Peter
Dimberg, Anna
Black, Peter
Tötterman, Thomas H
Mangsbo, Sara M

February 2017

Checkpoint blockade of CTLA-4 results in long-lasting survival benefits in metastatic cancer patient...

Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models.

Jonas Persson
Ines Beyer
Roma Yumul
ZongYi Li
Hans-Peter Kiem
Steve Roffler
André Lieber

Monoclonal antibodies specific for cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA4) are a no...

Treatment with agonistic anti-4-1BB and blocking anti-CTLA-4 delays tumor growth only in mice challenged with tumor cells expressing a strong foreign antigen.

Benjamin A. H. Jensen (421313)
Sara R. Pedersen (421314)
Jan P. Christensen (373499)
Allan R. Thomsen (421315)

June 2013

Mice (n = 8–10 mice/group) were inoculated s.c. in the right flank with 106 melanoma c...

The administration of PC61 further improves the efficacy of E6-RHDV-VLP-PADRE.

Khairunadwa Jemon (421993)
Vivienne Young (421994)
Michelle Wilson (421995)
Sara McKee (421996)
Vernon Ward (421997)
Margaret Baird (421998)
Sarah Young (158443)
Merilyn Hibma (421999)

June 2013

(a) Schematic diagram depicting the schedule of tumour administration, PC61 injection and the pri...

E6-RHDV-VLP-PADRE immunisation reduces tumour burden and increases survival in mice with pre-existing TC-1 tumours.

Khairunadwa Jemon (421993)
Vivienne Young (421994)
Michelle Wilson (421995)
Sara McKee (421996)
Vernon Ward (421997)
Margaret Baird (421998)
Sarah Young (158443)
Merilyn Hibma (421999)

June 2013

(a) C57BL/6 mice (eight per group) were inoculated with 1×105 TC-1 tumour cells/mouse ...

Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy

Sckisel, Gail D
Mirsoian, Annie
Bouchlaka, Myriam N
Tietze, Julia K
Chen, Mingyi
Blazar, Bruce R
Murphy, William J

December 2015

We have demonstrated that immunostimulatory therapies such as interleukin-2 (IL-2) and anti-CD40 (αC...

The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies.

Benjamin A H Jensen
Sara R Pedersen
Jan P Christensen
Allan R Thomsen

It has previously been found that combination therapy with anti-CTLA-4 and anti-4-1BB antibodies may...

The Availability of a Functional Tumor Targeting T-Cell Repertoire Determines the Anti-Tumor Efficiency of Combination Therapy with Anti-CTLA-4 and Anti-4-1BB Antibodies

Benjamin A. H. Jensen
Sara R. Pedersen
Jan P. Christensen
Allan R. Thomsen

August 2016

It has previously been found that combination therapy with anti-CTLA-4 and anti-4-1BB antibodies may...

Combined vaccination with immunotherapy cures large established tumors and provides protective immunity.

Priya Srinivasan (249011)
Xiaofang Wu (492585)
Mousumi Basu (4803894)
Christopher Rossi (4803897)
Anthony D. Sandler (501391)

January 2018

A/J mice were inoculated with 1 × 106 wild-type (WT) N2a, and once tumors were establi...

Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice

Ahern, Elizabeth
Harjunpaa, Heidi
Barkauskas, Deborah
Allen, Stacey
Takeda, Kazuyoshi
Yagita, Hideo
Wyld, David
Dougall, William C.
Teng, Michele W. L.
Smyth, Mark J.

October 2017

Purpose: Novel partners for established immune checkpoint inhibitors in the treatment of cancer are ...

CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice

Sabel, Michael S.
Chen, Fang-An
Hess, Stephen D.
Egilmez, Nejat K.
Conway, Thomas F.
Bankert, Richard B.

October 2005

Previous studies by others using transplantable murine tumor models have demonstrated that the admin...

Combined antibody therapy with agonistic anti-4-1BB and anti-CTLA-4 antibodies does not delay growth of B16.F10-GP tumors in GP tolerant Alb-1 mice.

Benjamin A. H. Jensen (421313)
Sara R. Pedersen (421314)
Jan P. Christensen (373499)
Allan R. Thomsen (421315)

June 2013

Mice (n = 10-11 mice/group) were inoculated s.c. in the right flank with 106 B16.F10-G...

Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer

Kuang Youlin
Zhang Li
Weng Xiaodong
Liu Xiuheng
Zhu Hengchen

January 2012

Immune regulation has been shown to be involved in the progressive growth of some murine tumours. In...

PD-1/CTLA-4 blockade increases the number of intra-tumor high endothelial venules, and enhances RANTES production in tumors.

Shi-Dong Ma (2746609)
Xuequn Xu (2746615)
Richard Jones (774144)
Henri-Jacques Delecluse (166065)
Nicholas A. Zumwalde (2746606)
Akshat Sharma (2746612)
Jenny E. Gumperz (215318)
Shannon C. Kenney (184312)

May 2016

A). Lymphomas from EBV-infected cord blood-humanized NSG mice treated with or without PD-1...

Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model

Field, Cameron S.
Hunn, Martin K.
Ferguson, Peter M.
Ruedl, Christiane
Ancelet, Lindsay R.
Hermans, Ian F.

January 2017

Vaccine-mediated cancer treatment is unlikely to induce long-term survival unless suppressive mechan...

Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer

van Hooren, Luuk
Sandin, Linda C
Moskalev, Igor
Ellmark, Peter
Dimberg, Anna
Black, Peter
Tötterman, Thomas H
Mangsbo, Sara M

February 2017

Checkpoint blockade of CTLA-4 results in long-lasting survival benefits in metastatic cancer patient...

Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models.

Jonas Persson
Ines Beyer
Roma Yumul
ZongYi Li
Hans-Peter Kiem
Steve Roffler
André Lieber

Monoclonal antibodies specific for cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA4) are a no...

Treatment with agonistic anti-4-1BB and blocking anti-CTLA-4 delays tumor growth only in mice challenged with tumor cells expressing a strong foreign antigen.

Benjamin A. H. Jensen (421313)
Sara R. Pedersen (421314)
Jan P. Christensen (373499)
Allan R. Thomsen (421315)

June 2013

Mice (n = 8–10 mice/group) were inoculated s.c. in the right flank with 106 melanoma c...

The administration of PC61 further improves the efficacy of E6-RHDV-VLP-PADRE.

Khairunadwa Jemon (421993)
Vivienne Young (421994)
Michelle Wilson (421995)
Sara McKee (421996)
Vernon Ward (421997)
Margaret Baird (421998)
Sarah Young (158443)
Merilyn Hibma (421999)

June 2013

(a) Schematic diagram depicting the schedule of tumour administration, PC61 injection and the pri...

E6-RHDV-VLP-PADRE immunisation reduces tumour burden and increases survival in mice with pre-existing TC-1 tumours.

Khairunadwa Jemon (421993)
Vivienne Young (421994)
Michelle Wilson (421995)
Sara McKee (421996)
Vernon Ward (421997)
Margaret Baird (421998)
Sarah Young (158443)
Merilyn Hibma (421999)

June 2013

(a) C57BL/6 mice (eight per group) were inoculated with 1×105 TC-1 tumour cells/mouse ...

Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy

Sckisel, Gail D
Mirsoian, Annie
Bouchlaka, Myriam N
Tietze, Julia K
Chen, Mingyi
Blazar, Bruce R
Murphy, William J

December 2015

We have demonstrated that immunostimulatory therapies such as interleukin-2 (IL-2) and anti-CD40 (αC...

The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies.

Benjamin A H Jensen
Sara R Pedersen
Jan P Christensen
Allan R Thomsen

It has previously been found that combination therapy with anti-CTLA-4 and anti-4-1BB antibodies may...

The Availability of a Functional Tumor Targeting T-Cell Repertoire Determines the Anti-Tumor Efficiency of Combination Therapy with Anti-CTLA-4 and Anti-4-1BB Antibodies

Benjamin A. H. Jensen
Sara R. Pedersen
Jan P. Christensen
Allan R. Thomsen

August 2016

It has previously been found that combination therapy with anti-CTLA-4 and anti-4-1BB antibodies may...

Combined vaccination with immunotherapy cures large established tumors and provides protective immunity.

Priya Srinivasan (249011)
Xiaofang Wu (492585)
Mousumi Basu (4803894)
Christopher Rossi (4803897)
Anthony D. Sandler (501391)

January 2018

A/J mice were inoculated with 1 × 106 wild-type (WT) N2a, and once tumors were establi...

Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice

Ahern, Elizabeth
Harjunpaa, Heidi
Barkauskas, Deborah
Allen, Stacey
Takeda, Kazuyoshi
Yagita, Hideo
Wyld, David
Dougall, William C.
Teng, Michele W. L.
Smyth, Mark J.

October 2017

Purpose: Novel partners for established immune checkpoint inhibitors in the treatment of cancer are ...

CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice

Sabel, Michael S.
Chen, Fang-An
Hess, Stephen D.
Egilmez, Nejat K.
Conway, Thomas F.
Bankert, Richard B.

October 2005

Previous studies by others using transplantable murine tumor models have demonstrated that the admin...

Combined antibody therapy with agonistic anti-4-1BB and anti-CTLA-4 antibodies does not delay growth of B16.F10-GP tumors in GP tolerant Alb-1 mice.

Benjamin A. H. Jensen (421313)
Sara R. Pedersen (421314)
Jan P. Christensen (373499)
Allan R. Thomsen (421315)

June 2013

Mice (n = 10-11 mice/group) were inoculated s.c. in the right flank with 106 B16.F10-G...

Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer

Kuang Youlin
Zhang Li
Weng Xiaodong
Liu Xiuheng
Zhu Hengchen

January 2012

Immune regulation has been shown to be involved in the progressive growth of some murine tumours. In...

PD-1/CTLA-4 blockade increases the number of intra-tumor high endothelial venules, and enhances RANTES production in tumors.

Shi-Dong Ma (2746609)
Xuequn Xu (2746615)
Richard Jones (774144)
Henri-Jacques Delecluse (166065)
Nicholas A. Zumwalde (2746606)
Akshat Sharma (2746612)
Jenny E. Gumperz (215318)
Shannon C. Kenney (184312)

May 2016

A). Lymphomas from EBV-infected cord blood-humanized NSG mice treated with or without PD-1...

Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model

Field, Cameron S.
Hunn, Martin K.
Ferguson, Peter M.
Ruedl, Christiane
Ancelet, Lindsay R.
Hermans, Ian F.

January 2017

Vaccine-mediated cancer treatment is unlikely to induce long-term survival unless suppressive mechan...

Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer

van Hooren, Luuk
Sandin, Linda C
Moskalev, Igor
Ellmark, Peter
Dimberg, Anna
Black, Peter
Tötterman, Thomas H
Mangsbo, Sara M

February 2017

Checkpoint blockade of CTLA-4 results in long-lasting survival benefits in metastatic cancer patient...

Anti-CTLA-4 blockade enhances the anti-tumour efficacy of E6-RHDV-VLP-PADRE immunisation.

Abstract

Extracted data

Anti-CTLA-4 blockade enhances the anti-tumour efficacy of E6-RHDV-VLP-PADRE immunisation.

Abstract

Extracted data

Related items

Related items